KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Net Margin (2016 - 2026)

Eli Lilly filings provide 17 years of Net Margin readings, the most recent being 37.36% for Q1 2026.

  • On a quarterly basis, Net Margin rose 1568.0% to 37.36% in Q1 2026 year-over-year; TTM through Mar 2026 was 34.99%, a 1232.0% increase, with the full-year FY2025 number at 31.67%, up 816.0% from a year prior.
  • Net Margin hit 37.36% in Q1 2026 for Eli Lilly, up from 34.41% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 37.36% in Q1 2026 to a low of 0.6% in Q3 2023.
  • Median Net Margin over the past 5 years was 24.36% (2022), compared with a mean of 23.78%.
  • Biggest five-year swings in Net Margin: tumbled -2152bps in 2023 and later skyrocketed 2323bps in 2025.
  • Eli Lilly's Net Margin stood at 26.54% in 2022, then fell by -12bps to 23.41% in 2023, then soared by 39bps to 32.59% in 2024, then rose by 6bps to 34.41% in 2025, then rose by 9bps to 37.36% in 2026.
  • The last three reported values for Net Margin were 37.36% (Q1 2026), 34.41% (Q4 2025), and 31.72% (Q3 2025) per Business Quant data.